


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.60%
-0.04%
+0.73%
+19.35%
NVS
Novartis AG
$156.42
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Technical Indicators

Overbought
NVS Price Performance
$141.54 (+10.51%)
$130.55 (+19.82%)
$123.31 (+26.85%)
$109.22 (+43.22%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Above analyst estimates

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
NVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVS Street Sentiment is bullish and have positive views on the near-term outlook
NVS has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
BUY
Date
Action
Rating
Firm
Dec 16, 2025
Reiterate
Neutral
Guggenheim
Dec 10, 2025
Upgrade
Overweight
JP Morgan
Dec 09, 2025
Upgrade
Overweight
JP Morgan
Nov 20, 2025
Upgrade
Buy
Morgan Stanley
PFE
Pfizer
27.22
+2.79%
AZN
Astrazeneca
193.03
+3.08%
SNY
Sanofi
47.83
+0.72%
MRK
Merck Company
121.93
+1.82%
REGN
Regeneron Pharma
785.51
+2.46%
What is NVS current stock price?
What are NVS stock strengths?
What is NVS Risk Level?
What is NVS market cap and volume?
What is NVS current Stock IQ?
Should I buy NVS stock right now?
Is NVS a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVS?
What does a 'Strong Sell' rating mean for NVS?
What factors influence NVS's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.60%
-0.04%
+0.73%
+19.35%
NVS
Novartis AG
Current Price
$156.42
Runners Also Watch
PFE
Pfizer
27.22
+2.79%
AZN
Astrazeneca
193.03
+3.08%
SNY
Sanofi
47.83
+0.72%
MRK
Merck Company
121.93
+1.82%
REGN
Regeneron Pharma
785.51
+2.46%

NVS Price Performance
$141.54 (+10.51%)
$130.55 (+19.82%)
$123.31 (+26.85%)
$109.22 (+43.22%)
NVS Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Reported a weak earnings

Above analyst estimates

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
NVS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVS Street Sentiment is bullish and have positive views on the near-term outlook
NVS has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
BUY
Dec 16, 2025
Reiterate
Neutral
Guggenheim
Dec 10, 2025
Upgrade
Overweight
JP Morgan
Dec 09, 2025
Upgrade
Overweight
JP Morgan
Nov 20, 2025
Upgrade
Buy
Morgan Stanley
NVS Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
Technical Indicators

Overbought
NVS Latest Analysis
Novartis: Value Price Growth Pipeline.
Thu Feb 5, 2026
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead. Swiss pharmaceutical NVS) reported fourth-quarter 2025 results on Wednesday.The company'.s net sales 1% year over year to $13.34 billion missing Wall Street'.s . On a constant-currency (cc) basis sales were down 1%.Generic competition had a negative impact of 15 percentage points including a negative impact of 3 percentage points from revenue deduction adjustments in the United States mainly related to Entresto and Promact
Wed Feb 4, 2026
Novartis Beats on Q4 Earnings Entresto Generics Pressure Sales. NVS tops Q4 EPS estimates as margins expand but revenues miss the mark amid United States generics hitting Entresto and Promacta reshaping its growth mix.
Wed Feb 4, 2026
Novartis reports mixed Q4 results. initiates FY26 soft outlook.
Wed Feb 4, 2026
Novartis reports mixed Q4 results. initates FY26 soft outlook.
Wed Feb 4, 2026
Novartis Q4 Profit Down Sales Rise. Sees Higher Sales In FY26 . (RTTNews) - Swiss drug major Novartis AG (NVS) reported Wednesday lower profit in its fourth quarter despite sales growth. Further the company lifted dividend and issued fiscal 2026 outlook expecting lower core operating income and higher net sales.
Wed Feb 4, 2026
Novartis delivered high single-digit sales growth achieved 40% core margin and further advanced the pipeline in 2025.
Wed Feb 4, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.